62 research outputs found

    Четыре клеточно-автоматных алгоритма пермутаций матриц

    Get PDF
    Numerical calculation uses to describe the operation of matrix permutation algorithms based on cyclic shifts of rows and columns. This choice of discrete transformation algorithms justified by the convenience of the cellular automaton (CA) formulation, which is used. Obtained Empirical formulas for the permutation period and for the last algorithm, which period formula is recurrent. For a base scheme period has the asymptotics:  for a matrix  with pairwise different elements. Despite the complexity of the scheme, the other two modifications only give a polynomial growth of period, no higher than 3. Fourth scheme has a non-trivial period dependence, but no higher than the exponential. In some cases algorithms make special permutations: rotate, reflect, and rearrange blocks for the matrix . These formulas are closely related to individual cells paths. And paths connected with the influence of the boundaries that gives branching the matrix order by subtraction class modulo 3,4 or 12. Visualizations of these paths make in the extended CA-field. Two "mixing metrics" analyze as a parameter of CA dynamics on matrix permutations (compared to the initial). For all schemes and most branches, the behavior of these metrics shows in graphs and histograms (conditional density distribution) showing how often the permutation period occurs with the specified interval of metrics. The practical aim of this work is in the field of pseudorandom number generation and cryptography.С помощью численного расчета описывается работа алгоритмов пермутаций матриц, основанных на циклических сдвигах строк и столбцов. Такой выбор алгоритмов дискретного преобразования обоснован удобством клеточно-автоматных формулировок, которые и приводятся. Получены эмпирические формулы для периода пермутаций; для последнего алгоритма формула периода носит рекуррентный характер. Для базовой и наиболее простой схемы период N(n) имеет асимптотику exp(2n)/n для матрицы nxn с попарно различными элементами. Несмотря на усложнение схемы алгоритма, две другие модификации дают лишь полиномиальный рост степени не выше 3. Четвертая схема имеет нетривиальную зависимость периода, но не выше экспоненциальной. В ряде случаев алгоритмы порождают особые пермутации: поворот, отражение и перестановку блоков для матрицы 2kx2k. Эти формулы тесно связаны с индивидуальными траекториями элементов, а они – с влиянием границ, что дает ветвление порядка матрицы по классу вычета по модулю 3,4 или 12. Визуализации этих траекторий приводятся в расширенном поле КА. В качестве параметра динамики КА анализируются две «метрики перемешанности» на пермутациях матрицы (по сравнению с начальной). Для всех схем и большинства ветвей поведение этих метрик представлено на графиках и гистограммах (условно: плотности распределения), показывающих, как часто встречаются по периоду пермутации с заданным интервалом значений метрик. Практическое значение работы состоит в оценке применения КА в областях генерации псевдослучайных чисел и криптографии

    Identification of a variant hotspot in MYBPC3 and of a novel CSRP3 autosomal recessive alteration in a cohort of Polish patients with hypertrophic cardiomyopathy

    Get PDF
    INTRODUCTION Hypertrophic cardiomyopathy (HCM) is a heart disorder caused by autosomal dominant alterations affecting both sarcomeric genes and other nonsarcomeric loci in a minority of cases. However, in some patients, the occurrence of the causal pathogenic variant or variants in homozygosity, compound heterozygosity, or double heterozygosity has also been described. Most of the HCM pathogenic variants are missense and unique, but truncating mutations of the MYBPC3 gene have been reported as founder pathogenic variants in populations from Finland, France, Japan, Iceland, Italy, and the Netherlands. OBJECTIVES This study aimed to assess the genetic background of HCM in a cohort of Polish patients. PATIENTS AND METHODS Twenty–nine Polish patients were analyzed by a next–generation sequencing panel including 404 cardiovascular genes. RESULTS Pathogenic variants were found in 41% of the patients, with ultra–rare MYBPC3 c.2541C>G (p.Tyr847Ter) mutation standing for a variant hotspot and correlating with a lower age at HCM diagnosis. Among the nonsarcomeric genes, the CSRP3 mutation was found in a single case carrying the novel c.364C>T (p.Arg122Ter) variant in homozygosity. With this finding, the total number of known HCM cases with human CSRP3 knockout cases has reached 3

    Creación de un Laboratorio de Análisis Socio-Político de América Latina (AMELAT -LAB)

    Get PDF
    El objetivo principal de este proyecto era crear un espacio de colaboración entre estudiantes, investigadores y profesores para el análisis y comprensión de problemáticas y fenómenos sociales y politicos actuales en América Latina

    Human telomerase activity regulation

    Get PDF
    Telomerase has been recognized as a relevant factor distinguishing cancer cells from normal cells. Thus, it has become a very promising target for anticancer therapy. The cell proliferative potential can be limited by replication end problem, due to telomeres shortening, which is overcome in cancer cells by telomerase activity or by alternative telomeres lengthening (ALT) mechanism. However, this multisubunit enzymatic complex can be regulated at various levels, including expression control but also other factors contributing to the enzyme phosphorylation status, assembling or complex subunits transport. Thus, we show that the telomerase expression targeting cannot be the only possibility to shorten telomeres and induce cell apoptosis. It is important especially since the transcription expression is not always correlated with the enzyme activity which might result in transcription modulation failure or a possibility for the gene therapy to be overcome. This review summarizes the current state of knowledge of numerous telomerase regulation mechanisms that take place after telomerase subunits coding genes transcription. Thus we show the possible mechanisms of telomerase activity regulation which might become attractive anticancer therapy targets

    Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

    Get PDF
    Cardiopoietic cells, produced through cardiogenic conditioning of patients' mesenchymal stem cells, have shown preliminary efficacy. The Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial aimed to validate cardiopoiesis-based biotherapy in a larger heart failure cohort
    corecore